Agmatín

Pôsobí na: náladu

Agmatín je metabolit L-Arginínu. Vykazuje sľubné výsledky pri zmierňovaní neuropatických bolestí a drogovej závislosti. Tiež vykazuje istý potenciál pri ochrane pred mŕtvicou a je prospešný pre kognitívne funkcie.

Užívanie

Pre užívanie agmatínu nemáme určenú štandardnú dávku, pretože zatiaľ chýba dostatok údajov o jeho pôsobení na ľudí. Vedecká štúdia, ktorá bola robená na ľuďoch liečených na neuropatické bolesti používala dávku 1300-2670 mg denne. Odhadovaná dávka pre zlepšenie kognitívnych funkcií u ľudí je 1,6-6,4 mg/kg podávaná orálne. Táto dávka je odhadnutá na základe pokusov na potkanoch. Dávka by nemala presiahnuť 6,4 mg/kg telesnej hmotnosti. Agmatín sa dobre nevstrebáva ak sa užíva spolu s proteínmi, pretože využíva rovnaký prenášač. Na potvrdenie jeho účinkov u ľudí sú potrebné ďalšie výskumy.

Medicínske upozornenie!

Literatúra

  1. Naila A, et al. Control of biogenic amines in food–existing and emerging approaches. J Food Sci. (2010)
  2. Molderings GJ, Haenisch B. Agmatine (decarboxylated L-arginine): physiological role and therapeutic potential. Pharmacol Ther. (2012)
  3. Holt A, Baker GB. Metabolism of agmatine (clonidine-displacing substance) by diamine oxidase and the possible implications for studies of imidazoline receptors. Prog Brain Res. (1995)
  4. Galgano F, et al. Focused review: agmatine in fermented foods. Front Microbiol. (2012)
  5. Authentication of Italian red wines on the basis of the polyphenols and biogenic amines.
  6. HPLC determination of agmatine and other amines in wine.
  7. De Borba BM, Rohrer JS. Determination of biogenic amines in alcoholic beverages by ion chromatography with suppressed conductivity detection and integrated pulsed amperometric detection. J Chromatogr A. (2007)
  8. The biogenic amine content of beer; the effect of barley, malting and brewing on amine concentration.
  9. Kvasnicka F, Voldrich M. Determination of biogenic amines by capillary zone electrophoresis with conductometric detection. J Chromatogr A. (2006)
  10. Okamoto A, et al. Polyamine content of ordinary foodstuffs and various fermented foods. Biosci Biotechnol Biochem. (1997)
  11. Profile and levels of bioactive amines in instant coffee.
  12. Ruiz-Capillas C, Jiménez-Colmenero F. Biogenic amines in meat and meat products. Crit Rev Food Sci Nutr. (2004)
  13. Lorenzo JM, et al. Biogenic amine content during the manufacture of dry-cured lacón, a Spanish traditional meat product: Effect of some additives. Meat Sci. (2007)
  14. Bover-Cid S, Izquierdo-Pulido M, Carmen Vidal-Carou M. Changes in biogenic amine and polyamine contents in slightly fermented sausages manufactured with and without sugar. Meat Sci. (2001)
  15. Consequences of high-pressure processing of vacuum-packaged frankfurters on the formation of polyamines: Effect of chilled storage.
  16. Biogenic amine changes in barramundi (Lates calcarifer) slices stored at 0 °C and 4 °C.
  17. Ruiz-Capillas C, Moral A. Free amino acids and biogenic amines in red and white muscle of tuna stored in controlled atmospheres. Amino Acids. (2004)
  18. Quality changes of anchovy (Stolephorus heterolobus) under refrigerated storage of different practical industrial methods in Thailand.
  19. Profile and levels of bioactive amines in green and roasted coffee.
  20. Monitoring of biologically active amines in cereals and cereal based food products by HPLC.
  21. Kirschbaum J, Rebscher K, Brückner H. Liquid chromatographic determination of biogenic amines in fermented foods after derivatization with 3,5-dinitrobenzoyl chloride. J Chromatogr A. (2000)
  22. Gründemann D, et al. Agmatine is efficiently transported by non-neuronal monoamine transporters extraneuronal monoamine transporter (EMT) and organic cation transporter 2 (OCT2). J Pharmacol Exp Ther. (2003)
  23. Steer H. The source of carbon dioxide for gastric acid production. Anat Rec (Hoboken). (2009)
  24. Jones TZ, et al. Interactions of imidazoline ligands with the active site of purified monoamine oxidase A. FEBS J. (2007)
  25. Remko M, Swart M, Bickelhaupt FM. Theoretical study of structure, pKa, lipophilicity, solubility, absorption, and polar surface area of some centrally acting antihypertensives. Bioorg Med Chem. (2006)
  26. Zhu MY, et al. Expression of human arginine decarboxylase, the biosynthetic enzyme for agmatine. Biochim Biophys Acta. (2004)
  27. Raasch W, et al. Agmatine is widely and unequally distributed in rat organs. Ann N Y Acad Sci. (1995)
  28. Raasch W, et al. Agmatine, the bacterial amine, is widely distributed in mammalian tissues. Life Sci. (1995)
  29. Iyer RK, et al. Cloning and characterization of human agmatinase. Mol Genet Metab. (2002)
  30. Mistry SK, et al. Cloning of human agmatinase. An alternate path for polyamine synthesis induced in liver by hepatitis B virus. Am J Physiol Gastrointest Liver Physiol. (2002)
  31. Haenisch B, et al. Regulatory mechanisms underlying agmatine homeostasis in humans. Am J Physiol Gastrointest Liver Physiol. (2008)
  32. Dallmann K, et al. Human agmatinase is diminished in the clear cell type of renal cell carcinoma. Int J Cancer. (2004)
  33. Bernstein HG, et al. Agmatinase, an inactivator of the putative endogenous antidepressant agmatine, is strongly upregulated in hippocampal interneurons of subjects with mood disorders. Neuropharmacology. (2012)
  34. Sastre M, et al. Metabolism of agmatine in macrophages: modulation by lipopolysaccharide and inhibitory cytokines. Biochem J. (1998)
  35. Haenisch B, et al. Effects of exogenous agmatine in human leukemia HMC-1 and HL-60 cells on proliferation, polyamine metabolism and cell cycle. Leuk Res. (2011)
  36. Regunathan S, et al. Imidazoline receptors and agmatine in blood vessels: a novel system inhibiting vascular smooth muscle proliferation. J Pharmacol Exp Ther. (1996)
  37. Gorbatyuk OS, et al. Localization of agmatine in vasopressin and oxytocin neurons of the rat hypothalamic paraventricular and supraoptic nuclei. Exp Neurol. (2001)
  38. Reis DJ, Yang XC, Milner TA. Agmatine containing axon terminals in rat hippocampus form synapses on pyramidal cells. Neurosci Lett. (1998)
  39. Otake K, et al. Regional localization of agmatine in the rat brain: an immunocytochemical study. Brain Res. (1998)
  40. Imidazoline Receptors and Their Endogenous Ligands.
  41. Wang H, et al. An antibody to agmatine localizes the amine in bovine adrenal chromaffin cells. Neurosci Lett. (1995)
  42. Molderings GJ, et al. Gastrointestinal uptake of agmatine: distribution in tissues and organs and pathophysiologic relevance. Ann N Y Acad Sci. (2003)
  43. Gilad GM, et al. Metabolism of agmatine into urea but not into nitric oxide in rat brain. Neuroreport. (1996)
  44. Komori Y, Wallace GC, Fukuto JM. Inhibition of purified nitric oxide synthase from rat cerebellum and macrophage by L-arginine analogs. Arch Biochem Biophys. (1994)
  45. Yokoi I, et al. Structure-activity relationships of arginine analogues on nitric oxide synthase activity in the rat brain. Neuropharmacology. (1994)
  46. Sennequier N, Stuehr DJ. Analysis of substrate-induced electronic, catalytic, and structural changes in inducible NO synthase. Biochemistry. (1996)
  47. Novotny WF, et al. Diamine oxidase is the amiloride-binding protein and is inhibited by amiloride analogues. J Biol Chem. (1994)
  48. McGrath AP, et al. A new crystal form of human diamine oxidase. Acta Crystallogr Sect F Struct Biol Cryst Commun. (2010)
  49. Cabella C, et al. Transport and metabolism of agmatine in rat hepatocyte cultures. Eur J Biochem. (2001)
  50. Mella C, et al. Expression and localization of an agmatinase-like protein in the rat brain. Histochem Cell Biol. (2010)
  51. Polo LM, et al. New insight into the transcarbamylase family: the structure of putrescine transcarbamylase, a key catalyst for fermentative utilization of agmatine. PLoS One. (2012)
  52. Satriano J, et al. Agmatine suppresses proliferation by frameshift induction of antizyme and attenuation of cellular polyamine levels. J Biol Chem. (1998)
  53. Babál P, et al. Regulation of ornithine decarboxylase activity and polyamine transport by agmatine in rat pulmonary artery endothelial cells. J Pharmacol Exp Ther. (2001)
  54. Satriano J, Kelly CJ, Blantz RC. An emerging role for agmatine. Kidney Int. (1999)
  55. Llácer JL, et al. The gene cluster for agmatine catabolism of Enterococcus faecalis: study of recombinant putrescine transcarbamylase and agmatine deiminase and a snapshot of agmatine deiminase catalyzing its reaction. J Bacteriol. (2007)
  56. Wargnies B, Lauwers N, Stalon V. Structure and properties of the putrescine carbamoyltransferase of Streptococcus faecalis. Eur J Biochem. (1979)
  57. Simon JP, Stalon V. Enzymes of agmatine degradation and the control of their synthesis in Streptococcus faecalis. J Bacteriol. (1982)
  58. Biosynthesis and metabolism of arginine in bacteria.
  59. Simon JP, Wargnies B, Stalon V. Control of enzyme synthesis in the arginine deiminase pathway of Streptococcus faecalis. J Bacteriol. (1982)
  60. Xi H, Schneider BL, Reitzer L. Purine catabolism in Escherichia coli and function of xanthine dehydrogenase in purine salvage. J Bacteriol. (2000)
  61. TIGIER H, GRISOLIA S. INDUCTION OF CARBAMYL-P SPECIFIC OXAMATE TRANSCARBAMYLASE BY PARABANIC ACID IN A STREPTOCOCCUS. Biochem Biophys Res Commun. (1965)
  62. Aricioglu F, Regunathan S, Piletz JE. Is agmatine an endogenous factor against stress. Ann N Y Acad Sci. (2003)
  63. Piletz JE, et al. Agmatine crosses the blood-brain barrier. Ann N Y Acad Sci. (2003)
  64. Feng Y, Halaris AE, Piletz JE. Determination of agmatine in brain and plasma using high-performance liquid chromatography with fluorescence detection. J Chromatogr B Biomed Sci Appl. (1997)
  65. Regunathan S, et al. Agmatine levels in the cerebrospinal fluid of normal human volunteers. J Pain Palliat Care Pharmacother. (2009)
  66. Jo I, et al. Low levels of plasma agmatine in the metabolic syndrome. Metab Syndr Relat Disord. (2010)
  67. Li G, et al. Agmatine: an endogenous clonidine-displacing substance in the brain. Science. (1994)
  68. Uzbay T, et al. Increased plasma agmatine levels in patients with schizophrenia. J Psychiatr Res. (2013)
  69. Halaris A, et al. Plasma agmatine and platelet imidazoline receptors in depression. Ann N Y Acad Sci. (1999)
  70. Molderings GJ, et al. Exposure of rat isolated stomach and rats in vivo to {(14)C}agmatine: accumulation in the stomach wall and distribution in various tissues. Fundam Clin Pharmacol. (2002)
  71. Li YF, et al. Antidepressant-like effect of agmatine and its possible mechanism. Eur J Pharmacol. (2003)
  72. Roberts JC, et al. Pharmacodynamic and pharmacokinetic studies of agmatine after spinal administration in the mouse. J Pharmacol Exp Ther. (2005)
  73. Raasch W, et al. Agmatine, an endogenous ligand at imidazoline binding sites, does not antagonize the clonidine-mediated blood pressure reaction. Br J Pharmacol. (2002)
  74. Satriano J, et al. Polyamine transport system mediates agmatine transport in mammalian cells. Am J Physiol Cell Physiol. (2001)
  75. Agmatine Is Efficiently Transported by Non-Neuronal Monoamine Transporters Extraneuronal Monoamine Transporter (EMT) and Organic Cation Transporter 2 (OCT2).
  76. Agmatine Is Synthesized by a Mitochondrial Arginine Decarboxylase in Rat Brain.
  77. Endogenous pain modulation: Neuropharmacokinetic/dynamic studies of the endogenous NMDA receptor antagonist/NOS inhibitor, agmatine.
  78. Reis DJ, Regunathan S. Agmatine: a novel neurotransmitter. Adv Pharmacol. (1998)
  79. Sastre M, et al. Agmatinase activity in rat brain: a metabolic pathway for the degradation of agmatine. J Neurochem. (1996)
  80. Goracke-Postle CJ, et al. Release of tritiated agmatine from spinal synaptosomes. Neuroreport. (2006)
  81. Sastre M, Regunathan S, Reis DJ. Uptake of agmatine into rat brain synaptosomes: possible role of cation channels. J Neurochem. (1997)
  82. Goracke-Postle CJ, et al. Potassium- and capsaicin-induced release of agmatine from spinal nerve terminals. J Neurochem. (2007)
  83. Goracke-Postle CJ, et al. Agmatine transport into spinal nerve terminals is modulated by polyamine analogs. J Neurochem. (2007)
  84. Regunathan S, et al. Agmatine (decarboxylated arginine) is synthesized and stored in astrocytes. Neuroreport. (1995)
  85. Zomkowski AD, Santos AR, Rodrigues AL. Putrescine produces antidepressant-like effects in the forced swimming test and in the tail suspension test in mice. Prog Neuropsychopharmacol Biol Psychiatry. (2006)
  86. Molderings GJ, et al. Dual interaction of agmatine with the rat alpha(2D)-adrenoceptor: competitive antagonism and allosteric activation. Br J Pharmacol. (2000)
  87. Dias Elpo Zomkowski A, et al. Evidence for serotonin receptor subtypes involvement in agmatine antidepressant like-effect in the mouse forced swimming test. Brain Res. (2004)
  88. Gibson DA, et al. Radioligand binding studies reveal agmatine is a more selective antagonist for a polyamine-site on the NMDA receptor than arcaine or ifenprodil. Brain Res. (2002)
  89. Lewin AH, et al. Molecular features associated with polyamine modulation of NMDA receptors. J Med Chem. (1998)
  90. Jiang XZ, et al. 5-HT1A/1B receptors, alpha2-adrenoceptors and the post-receptor adenylate cyclase activation in the mice brain are involved in the antidepressant-like action of agmatine. Yao Xue Xue Bao. (2008)
  91. Piletz JE, Chikkala DN, Ernsberger P. Comparison of the properties of agmatine and endogenous clonidine-displacing substance at imidazoline and alpha-2 adrenergic receptors. J Pharmacol Exp Ther. (1995)
  92. Morrissey JJ, Klahr S. Agmatine activation of nitric oxide synthase in endothelial cells. Proc Assoc Am Physicians. (1997)
  93. Chang CH, et al. Increase of beta-endorphin secretion by agmatine is induced by activation of imidazoline I(2A) receptors in adrenal gland of rats. Neurosci Lett. (2010)
  94. Pinthong D, et al. Comparison of the interaction of agmatine and crude methanolic extracts of bovine lung and brain with alpha 2-adrenoceptor binding sites. Br J Pharmacol. (1995)
  95. Pinthong D, et al. Agmatine recognizes alpha 2-adrenoceptor binding sites but neither activates nor inhibits alpha 2-adrenoceptors. Naunyn Schmiedebergs Arch Pharmacol. (1995)
  96. Pinthong D, et al. No evidence for activation of alpha(2)-adrenoceptors by methanolic extracts of bovine brain and lung containing clonidine-displacing substance. Ann N Y Acad Sci. (2003)
  97. Taksande BG, et al. Agmatine in the hypothalamic paraventricular nucleus stimulates feeding in rats: involvement of neuropeptide Y. Br J Pharmacol. (2011)
  98. Zomkowski AD, et al. Agmatine produces antidepressant-like effects in two models of depression in mice. Neuroreport. (2002)
  99. Ozaita A, et al. Inhibition of monoamine oxidase A and B activities by imidazol(ine)/guanidine drugs, nature of the interaction and distinction from I2-imidazoline receptors in rat liver. Br J Pharmacol. (1997)
  100. Raasch W, Muhle H, Dominiak P. Modulation of MAO activity by imidazoline and guanidine derivatives. Ann N Y Acad Sci. (1999)
  101. Regunathan S, Meeley MP, Reis DJ. Expression of non-adrenergic imidazoline sites in chromaffin cells and mitochondrial membranes of bovine adrenal medulla. Biochem Pharmacol. (1993)
  102. Head GA, Mayorov DN. Imidazoline receptors, novel agents and therapeutic potential. Cardiovasc Hematol Agents Med Chem. (2006)
  103. González C, et al. Agmatine, an endogenous modulator of noradrenergic neurotransmission in the rat tail artery. Br J Pharmacol. (1996)
  104. Molderings GJ, Göthert M. Inhibitory presynaptic imidazoline receptors on sympathetic nerves in the rabbit aorta differ from I1- and I2-imidazoline binding sites. Naunyn Schmiedebergs Arch Pharmacol. (1995)
  105. Askalany AR, et al. Effect of agmatine on heteromeric N-methyl-D-aspartate receptor channels. Neurosci Res. (2005)
  106. Yang XC, Reis DJ. Agmatine selectively blocks the N-methyl-D-aspartate subclass of glutamate receptor channels in rat hippocampal neurons. J Pharmacol Exp Ther. (1999)
  107. Reynolds IJ. Arcaine uncovers dual interactions of polyamines with the N-methyl-D-aspartate receptor. J Pharmacol Exp Ther. (1990)
  108. Anis N, et al. Structure-activity relationships of philanthotoxin analogs and polyamines on N-methyl-D-aspartate and nicotinic acetylcholine receptors. J Pharmacol Exp Ther. (1990)
  109. Zhu MY, et al. Effect of agmatine against cell death induced by NMDA and glutamate in neurons and PC12 cells. Cell Mol Neurobiol. (2003)
  110. Brown RE, Stevens DR, Haas HL. The physiology of brain histamine. Prog Neurobiol. (2001)
  111. Burban A, et al. Histamine potentiates N-methyl-D-aspartate receptors by interacting with an allosteric site distinct from the polyamine binding site. J Pharmacol Exp Ther. (2010)
  112. Watanabe C, et al. Intrathecal high-dose histamine induces spinally-mediated nociceptive behavioral responses through a polyamine site of NMDA receptors. Eur J Pharmacol. (2008)
  113. Wade CL, et al. Immunoneutralization of agmatine sensitizes mice to micro-opioid receptor tolerance. J Pharmacol Exp Ther. (2009)
  114. Lewis B, Wellmann KA, Barron S. Agmatine reduces balance deficits in a rat model of third trimester binge-like ethanol exposure. Pharmacol Biochem Behav. (2007)
  115. Barron S, et al. Polyamine modulation of NMDARs as a mechanism to reduce effects of alcohol dependence. Recent Pat CNS Drug Discov. (2012)
  116. Rawls SM, Gomez T, Raffa RB. An NMDA antagonist (LY 235959) attenuates abstinence-induced withdrawal of planarians following acute exposure to a cannabinoid agonist (WIN 55212-2). Pharmacol Biochem Behav. (2007)
  117. Demady DR, et al. Agmatine enhances the NADPH oxidase activity of neuronal NO synthase and leads to oxidative inactivation of the enzyme. Mol Pharmacol. (2001)
  118. Nishida CR, Ortiz de Montellano PR. Electron transfer and catalytic activity of nitric oxide synthases. Chimeric constructs of the neuronal, inducible, and endothelial isoforms. J Biol Chem. (1998)
  119. Abu-Soud HM, et al. Electron transfer in the nitric-oxide synthases. Characterization of L-arginine analogs that block heme iron reduction. J Biol Chem. (1994)
  120. Alagarsamy S, Johnson KM. Voltage-dependent calcium channel involvement in NMDA-induced activation of NOS. Neuroreport. (1995)
  121. Fairbanks CA, Wilcox GL. Acute tolerance to spinally administered morphine compares mechanistically with chronically induced morphine tolerance. J Pharmacol Exp Ther. (1997)
  122. Kolesnikov YA, et al. Blockade of tolerance to morphine but not to kappa opioids by a nitric oxide synthase inhibitor. Proc Natl Acad Sci U S A. (1993)
  123. Elliott K, et al. The NMDA receptor antagonists, LY274614 and MK-801, and the nitric oxide synthase inhibitor, NG-nitro-L-arginine, attenuate analgesic tolerance to the mu-opioid morphine but not to kappa opioids. Pain. (1994)
  124. Elliott K, et al. N-methyl-D-aspartate (NMDA) receptors, mu and kappa opioid tolerance, and perspectives on new analgesic drug development. Neuropsychopharmacology. (1995)
  125. Loring RH. Agmatine acts as an antagonist of neuronal nicotinic receptors. Br J Pharmacol. (1990)
  126. Krass M, et al. Antidepressant-like effect of agmatine is not mediated by serotonin. Behav Brain Res. (2008)
  127. Molderings GJ, et al. Inhibition of 5-HT3 receptor function by imidazolines in mouse neuroblastoma cells: potential involvement of sigma 2 binding sites. Naunyn Schmiedebergs Arch Pharmacol. (1996)
  128. Taksande BG, et al. Antidepressant like effect of selective serotonin reuptake inhibitors involve modulation of imidazoline receptors by agmatine. Neuropharmacology. (2009)
  129. Kim HS, et al. NMDA receptor antagonists enhance 5-HT2 receptor-mediated behavior, head-twitch response, in PCPA-treated mice. Arch Pharm Res. (1999)
  130. Kim HS, Son YR, Kim SH. Nitric oxide synthase inhibitors enhance 5-HT2 receptor-mediated behavior, the head-twitch response in mice. Life Sci. (1999)
  131. Kotagale NR, et al. Evidences for the agmatine involvement in antidepressant like effect of bupropion in mouse forced swim test. Pharmacol Biochem Behav. (2013)
  132. Tsou K, et al. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience. (1998)
  133. Pettit DA, et al. Immunohistochemical localization of the neural cannabinoid receptor in rat brain. J Neurosci Res. (1998)
  134. Ruggiero DA, et al. Immunocytochemical localization of an imidazoline receptor protein in the central nervous system. Brain Res. (1998)
  135. Molderings GJ, Likungu J, Göthert M. Presynaptic cannabinoid and imidazoline receptors in the human heart and their potential relationship. Naunyn Schmiedebergs Arch Pharmacol. (1999)
  136. Aggarwal S, et al. Agmatine enhances cannabinoid action in the hot-plate assay of thermal nociception. Pharmacol Biochem Behav. (2009)
  137. Rawls SM, Tallarida RJ, Zisk J. Agmatine and a cannabinoid agonist, WIN 55212-2, interact to produce a hypothermic synergy. Eur J Pharmacol. (2006)
  138. Compton DR, et al. Aminoalkylindole analogs: cannabimimetic activity of a class of compounds structurally distinct from delta 9-tetrahydrocannabinol. J Pharmacol Exp Ther. (1992)
  139. Thorat SN, Bhargava HN. Effects of NMDA receptor blockade and nitric oxide synthase inhibition on the acute and chronic actions of delta 9-tetrahydrocannabinol in mice. Brain Res. (1994)
  140. Spina E, et al. A role of nitric oxide in WIN 55,212-2 tolerance in mice. Eur J Pharmacol. (1998)
  141. Molderings GJ, et al. Presynaptic imidazoline receptors and non-adrenoceptor {3H}-idazoxan binding sites in human cardiovascular tissues. Br J Pharmacol. (1997)
  142. Wong CS, et al. Effects of NMDA receptor antagonists on inhibition of morphine tolerance in rats: binding at mu-opioid receptors. Eur J Pharmacol. (1996)
  143. Li J, et al. Effects of agmatine on tolerance to and substance dependence on morphine in mice. Zhongguo Yao Li Xue Bao. (1999)
  144. Kolesnikov Y, Jain S, Pasternak GW. Modulation of opioid analgesia by agmatine. Eur J Pharmacol. (1996)
  145. Yeşilyurt O, Uzbay IT. Agmatine potentiates the analgesic effect of morphine by an alpha(2)-adrenoceptor-mediated mechanism in mice. Neuropsychopharmacology. (2001)
  146. Bhalla S, Rapolaviciute V, Gulati A. Determination of α(2)-adrenoceptor and imidazoline receptor involvement in augmentation of morphine and oxycodone analgesia by agmatine and BMS182874. Eur J Pharmacol. (2011)
  147. Su RB, et al. Effects of intragastric agmatine on morphine-induced physiological dependence in beagle dogs and rhesus monkeys. Eur J Pharmacol. (2008)
  148. Gold MS, Redmond DE Jr, Kleber HD. Clonidine blocks acute opiate-withdrawal symptoms. Lancet. (1978)
  149. Kosten TA. Clonidine attenuates conditioned aversion produced by naloxone-precipitated opiate withdrawal. Eur J Pharmacol. (1994)
  150. Maldonado R. Participation of noradrenergic pathways in the expression of opiate withdrawal: biochemical and pharmacological evidence. Neurosci Biobehav Rev. (1997)
  151. Iglesias V, et al. Effects of yohimbine on morphine analgesia and physical dependence in the rat. Eur J Pharmacol. (1992)
  152. Dwoskin LP, Neal BS, Sparber SB. Yohimbine exacerbates and clonidine attenuates acute morphine withdrawal in rats. Eur J Pharmacol. (1983)
  153. Wade CL, et al. Supraspinally-administered agmatine attenuates the development of oral fentanyl self-administration. Eur J Pharmacol. (2008)
  154. Morgan AD, et al. Effects of agmatine on the escalation of intravenous cocaine and fentanyl self-administration in rats. Pharmacol Biochem Behav. (2002)
  155. Huston JP, et al. What’s conditioned in conditioned place preference. Trends Pharmacol Sci. (2013)
  156. Tahsili-Fahadan P, et al. Agmatine potentiates morphine-induced conditioned place preference in mice: modulation by alpha2-adrenoceptors. Neuropsychopharmacology. (2006)
  157. Yu Y, et al. A nonproton ligand sensor in the acid-sensing ion channel. Neuron. (2010)
  158. Li WG, et al. ASIC3 channels integrate agmatine and multiple inflammatory signals through the nonproton ligand sensing domain. Mol Pain. (2010)
  159. Wemmie JA, Price MP, Welsh MJ. Acid-sensing ion channels: advances, questions and therapeutic opportunities. Trends Neurosci. (2006)
  160. Waldmann R, et al. A proton-gated cation channel involved in acid-sensing. Nature. (1997)
  161. de Weille JR, et al. Identification, functional expression and chromosomal localisation of a sustained human proton-gated cation channel. FEBS Lett. (1998)
  162. Salinas M, Lazdunski M, Lingueglia E. Structural elements for the generation of sustained currents by the acid pain sensor ASIC3. J Biol Chem. (2009)
  163. Deval E, et al. ASIC3, a sensor of acidic and primary inflammatory pain. EMBO J. (2008)
  164. Li WG, Xu TL. ASIC3 channels in multimodal sensory perception. ACS Chem Neurosci. (2011)
  165. Zhang M, Wang H, Tracey KJ. Regulation of macrophage activation and inflammation by spermine: a new chapter in an old story. Crit Care Med. (2000)
  166. Fairbanks CA, et al. Agmatine reverses pain induced by inflammation, neuropathy, and spinal cord injury. Proc Natl Acad Sci U S A. (2000)
  167. Su RB, Li J, Qin BY. A biphasic opioid function modulator: agmatine. Acta Pharmacol Sin. (2003)
  168. Keynan O, et al. Safety and Efficacy of Dietary Agmatine Sulfate in Lumbar Disc-associated Radiculopathy. An Open-label, Dose-escalating Study Followed by a Randomized, Double-blind, Placebo-controlled Trial. Pain Med. (2010)
  169. Buchhalter AR, Fant RV, Henningfield JE. Novel pharmacological approaches for treating tobacco dependence and withdrawal: current status. Drugs. (2008)
  170. Gourlay S, et al. A placebo-controlled study of three clonidine doses for smoking cessation. Clin Pharmacol Ther. (1994)
  171. Yamanaka K, Oshita M, Muramatsu I. Alteration of alpha and muscarinic receptors in rat brain and heart following chronic nicotine treatment. Brain Res. (1985)
  172. Kotagale NR, et al. Repeated agmatine treatment attenuates nicotine sensitization in mice: modulation by alpha2-adrenoceptors. Behav Brain Res. (2010)
  173. Zaniewska M, et al. Effects of agmatine on nicotine-evoked behavioral responses in rats. Pharmacol Rep. (2008)
  174. Uzbay IT, et al. Effects of agmatine on ethanol withdrawal syndrome in rats. Behav Brain Res. (2000)
  175. Taksande BG, et al. Agmatine, an endogenous imidazoline receptor ligand modulates ethanol anxiolysis and withdrawal anxiety in rats. Eur J Pharmacol. (2010)
  176. Littleton JM, et al. Role of polyamines and NMDA receptors in ethanol dependence and withdrawal. Alcohol Clin Exp Res. (2001)
  177. Gibson DA, et al. Polyamines contribute to ethanol withdrawal-induced neurotoxicity in rat hippocampal slice cultures through interactions with the NMDA receptor. Alcohol Clin Exp Res. (2003)
  178. Collins ED, et al. The effects of memantine on the subjective, reinforcing and cardiovascular effects of cocaine in humans. Behav Pharmacol. (1998)
  179. Collins ED, et al. The effects of acute pretreatment with high-dose memantine on the cardiovascular and behavioral effects of cocaine in humans. Exp Clin Psychopharmacol. (2007)
  180. Rawls SM, et al. A nitric oxide synthase inhibitor (L-NAME) attenuates abstinence-induced withdrawal from both cocaine and a cannabinoid agonist (WIN 55212-2) in Planaria. Brain Res. (2006)
  181. Cantin L, et al. Cocaine is low on the value ladder of rats: possible evidence for resilience to addiction. PLoS One. (2010)
  182. Lenoir M, et al. Intense sweetness surpasses cocaine reward. PLoS One. (2007)
  183. Wang CC, et al. Beneficial effect of agmatine on brain apoptosis, astrogliosis, and edema after rat transient cerebral ischemia. BMC Pharmacol. (2010)
  184. Agmatine reduced the expressions of nitric oxide synthase and peroxynitrite formation in rat cerebral cortex after transient global cerebral ischemia.
  185. Kim JH, et al. Agmatine attenuates brain edema through reducing the expression of aquaporin-1 after cerebral ischemia. J Cereb Blood Flow Metab. (2010)
  186. Lee WT, et al. Neuroprotective effects of agmatine on oxygen-glucose deprived primary-cultured astrocytes and nuclear translocation of nuclear factor-kappa B. Brain Res. (2009)
  187. Kim JH, et al. Agmatine reduces infarct area in a mouse model of transient focal cerebral ischemia and protects cultured neurons from ischemia-like injury. Exp Neurol. (2004)
  188. Feng Y, Piletz JE, Leblanc MH. Agmatine suppresses nitric oxide production and attenuates hypoxic-ischemic brain injury in neonatal rats. Pediatr Res. (2002)
  189. Iadecola C. Bright and dark sides of nitric oxide in ischemic brain injury. Trends Neurosci. (1997)
  190. Moro MA, et al. Role of nitric oxide after brain ischaemia. Cell Calcium. (2004)
  191. Raghavan SA, Dikshit M. Vascular regulation by the L-arginine metabolites, nitric oxide and agmatine. Pharmacol Res. (2004)
  192. Huang Z, et al. Effects of cerebral ischemia in mice deficient in neuronal nitric oxide synthase. Science. (1994)
  193. Mun CH, et al. Regulation of endothelial nitric oxide synthase by agmatine after transient global cerebral ischemia in rat brain. Anat Cell Biol. (2010)
  194. Ma T, et al. Generation and phenotype of a transgenic knockout mouse lacking the mercurial-insensitive water channel aquaporin-4. J Clin Invest. (1997)
  195. Manley GT, et al. Aquaporin-4 deletion in mice reduces brain edema after acute water intoxication and ischemic stroke. Nat Med. (2000)
  196. Ribeiro Mde C, et al. Time course of aquaporin expression after transient focal cerebral ischemia in mice. J Neurosci Res. (2006)
  197. Gilad GM, et al. Agmatine treatment is neuroprotective in rodent brain injury models. Life Sci. (1996)
  198. Panet H, et al. Activation of nuclear transcription factor kappa B (NF-kappaB) is essential for dopamine-induced apoptosis in PC12 cells. J Neurochem. (2001)
  199. Seo SK, et al. Overexpression of human arginine decarboxylase rescues human mesenchymal stem cells against H₂O₂ toxicity through cell survival protein activation. J Korean Med Sci. (2013)
  200. Santhanam AV, Viswanathan S, Dikshit M. Activation of protein kinase B/Akt and endothelial nitric oxide synthase mediates agmatine-induced endothelium-dependent relaxation. Eur J Pharmacol. (2007)
  201. Li W, et al. An essential role for the Id1/PI3K/Akt/NFkB/survivin signalling pathway in promoting the proliferation of endothelial progenitor cells in vitro. Mol Cell Biochem. (2012)
  202. Kanwar JR, Kamalapuram SK, Kanwar RK. Targeting survivin in cancer: the cell-signalling perspective. Drug Discov Today. (2011)
  203. Lin J, et al. Inhibitor of differentiation 1 contributes to head and neck squamous cell carcinoma survival via the NF-kappaB/survivin and phosphoinositide 3-kinase/Akt signaling pathways. Clin Cancer Res. (2010)
  204. Young ND, Galston AW. Putrescine and Acid Stress : Induction of Arginine Decarboxylase Activity and Putrescine Accumulation by Low pH. Plant Physiol. (1983)
  205. Bliven KA, Fisher DJ, Maurelli AT. Characterization of the activity and expression of arginine decarboxylase in human and animal Chlamydia pathogens. FEMS Microbiol Lett. (2012)
  206. Pothipongsa A, Jantaro S, Incharoensakdi A. Polyamines induced by osmotic stress protect Synechocystis sp. PCC 6803 cells and arginine decarboxylase transcripts against UV-B radiation. Appl Biochem Biotechnol. (2012)
  207. Xu X, Shi G, Jia R. Changes of polyamine levels in roots of Sagittaria sagittifolia L. under copper stress. Environ Sci Pollut Res Int. (2011)
  208. Ruiz-Durántez E, et al. Effect of agmatine on locus coeruleus neuron activity: possible involvement of nitric oxide. Br J Pharmacol. (2002)
  209. Weiss JM, et al. Depression and anxiety: role of the locus coeruleus and corticotropin-releasing factor. Brain Res Bull. (1994)
  210. Lavinsky D, Arteni NS, Netto CA. Agmatine induces anxiolysis in the elevated plus maze task in adult rats. Behav Brain Res. (2003)
  211. Aricioglu F, Altunbas H. Is agmatine an endogenous anxiolytic/antidepressant agent. Ann N Y Acad Sci. (2003)
  212. Gong ZH, et al. Anxiolytic effect of agmatine in rats and mice. Eur J Pharmacol. (2006)
  213. Halaris A, Piletz JE. Relevance of imidazoline receptors and agmatine to psychiatry: a decade of progress. Ann N Y Acad Sci. (2003)
  214. Kaster MP, et al. Effects of potassium channel inhibitors in the forced swimming test: possible involvement of L-arginine-nitric oxide-soluble guanylate cyclase pathway. Behav Brain Res. (2005)
  215. Zomkowski AD, Santos AR, Rodrigues AL. Evidence for the involvement of the opioid system in the agmatine antidepressant-like effect in the forced swimming test. Neurosci Lett. (2005)
  216. Budni J, et al. Role of different types of potassium channels in the antidepressant-like effect of agmatine in the mouse forced swimming test. Eur J Pharmacol. (2007)
  217. Fluoxetine inhibits A-type potassium currents in primary cultured rat hippocampal neurons.
  218. Differential blockade of neuronal voltage-gated Na+ and K+ channels by antidepressant drugs.
  219. Inhibition of G Protein-Activated Inwardly Rectifying K+ Channels by Phencyclidine.
  220. Kobayashi T, Washiyama K, Ikeda K. Inhibition of G protein-activated inwardly rectifying K+ channels by various antidepressant drugs. Neuropsychopharmacology. (2004)
  221. Kaster MP, et al. The inhibition of different types of potassium channels underlies the antidepressant-like effect of adenosine in the mouse forced swimming test. Prog Neuropsychopharmacol Biol Psychiatry. (2007)
  222. Budni J, et al. Role of potassium channels in the antidepressant-like effect of folic acid in the forced swimming test in mice. Pharmacol Biochem Behav. (2012)
  223. Redrobe JP, Pinot P, Bourin M. The effect of the potassium channel activator, cromakalim, on antidepressant drugs in the forced swimming test in mice. Fundam Clin Pharmacol. (1996)
  224. Bortolatto CF, et al. Involvement of potassium channels in the antidepressant-like effect of venlafaxine in mice. Life Sci. (2010)
  225. Kelly JS, et al. Serotonin receptor heterogeneity and the role of potassium channels in neuronal excitability. Adv Exp Med Biol. (1991)
  226. Weng XC, et al. Agmatine blocked voltage-gated calcium channel in cultured rat hippocampal neurons. Acta Pharmacol Sin. (2003)
  227. The clinical antidepressant effect of exogenous agmatine is not reversed by parachlorophenylalanine: a pilot study.
  228. Pedrazzini T, Pralong F, Grouzmann E. Neuropeptide Y: the universal soldier. Cell Mol Life Sci. (2003)
  229. Kask A, Rägo L, Harro J. Evidence for involvement of neuropeptide Y receptors in the regulation of food intake: studies with Y1-selective antagonist BIBP3226. Br J Pharmacol. (1998)
  230. Huguet F, et al. Age-related changes of noradrenergic-NPY interaction in rat brain: norepinephrine, NPY levels and alpha-adrenoceptors. Brain Res. (1993)
  231. Sawchenko PE, et al. Colocalization of neuropeptide Y immunoreactivity in brainstem catecholaminergic neurons that project to the paraventricular nucleus of the hypothalamus. J Comp Neurol. (1985)
  232. Everitt BJ, et al. Differential co-existence of neuropeptide Y (NPY)-like immunoreactivity with catecholamines in the central nervous system of the rat. Neuroscience. (1984)
  233. Franco-Cereceda A, et al. Differential effects of clonidine and reserpine treatment on neuropeptide Y content in some sympathetically innervated tissues of the guinea-pig. Eur J Pharmacol. (1987)
  234.  Smiałowska M, et al. Clonidine administration increases neuropeptide Y immunoreactivity and neuropeptide Y mRNA in the rat cerebral cortex neurons. Neuropeptides. (1997)
  235. Clark JT, et al. Alpha 2-adrenoceptor blockade attenuates feeding behavior induced by neuropeptide Y and epinephrine. Physiol Behav. (1988)
  236. Heilig M, Wahlestedt C, Widerlöv E. Neuropeptide Y (NPY)-induced suppression of activity in the rat: evidence for NPY receptor heterogeneity and for interaction with alpha-adrenoceptors. Eur J Pharmacol. (1988)
  237. Prasad A, Prasad C. Agmatine enhances caloric intake and dietary carbohydrate preference in satiated rats. Physiol Behav. (1996)
  238. Seo S, Liu P, Leitch B. Spatial learning-induced accumulation of agmatine and glutamate at hippocampal CA1 synaptic terminals. Neuroscience. (2011)
  239. Betancourt L, et al. In vivo monitoring of cerebral agmatine by microdialysis and capillary electrophoresis. J Chromatogr B Analyt Technol Biomed Life Sci. (2012)
  240. Liu P, et al. Spatial learning results in elevated agmatine levels in the rat brain. Hippocampus. (2008)
  241. Leitch B, et al. Spatial learning-induced increase in agmatine levels at hippocampal CA1 synapses. Synapse. (2011)
  242. Rushaidhi M, et al. Participation of hippocampal agmatine in spatial learning: an in vivo microdialysis study. Neuropharmacology. (2013)
  243. Wang ZM, et al. Effects of agmatine on neuronal discharges in rat hippocampal CA1 area. Sheng Li Xue Bao. (2003)
  244. Liu P, et al. Memory-related changes in L-citrulline and agmatine in the rat brain. Hippocampus. (2009)
  245. Arteni NS, et al. Agmatine facilitates memory of an inhibitory avoidance task in adult rats. Neurobiol Learn Mem. (2002)
  246. Zhou HC, et al. Activation of β2-adrenoceptor enhances synaptic potentiation and behavioral memory via cAMP-PKA signaling in the medial prefrontal cortex of rats. Learn Mem. (2013)
  247. Dalley JW, Cardinal RN, Robbins TW. Prefrontal executive and cognitive functions in rodents: neural and neurochemical substrates. Neurosci Biobehav Rev. (2004)
  248. Gaffan D, Parker A. Interaction of perirhinal cortex with the fornix-fimbria: memory for objects and „object-in-place“ memory. J Neurosci. (1996)
  249. Riccio A, et al. Mediation by a CREB family transcription factor of NGF-dependent survival of sympathetic neurons. Science. (1999)
  250. Du K, Montminy M. CREB is a regulatory target for the protein kinase Akt/PKB. J Biol Chem. (1998)
  251. Chen X, et al. Ischemic rat brain extracts induce human marrow stromal cell growth factor production. Neuropathology. (2002)
  252. Lu Y, Christian K, Lu B. BDNF: a key regulator for protein synthesis-dependent LTP and long-term memory. Neurobiol Learn Mem. (2008)
  253. Collingridge GL, Bliss TV. Memories of NMDA receptors and LTP. Trends Neurosci. (1995)
  254. Cain DP. LTP, NMDA, genes and learning. Curr Opin Neurobiol. (1997)
  255. Hawkins RD, Son H, Arancio O. Nitric oxide as a retrograde messenger during long-term potentiation in hippocampus. Prog Brain Res. (1998)
  256. Yananli H, et al. Effect of agmatine on brain L-citrulline production during morphine withdrawal in rats: a microdialysis study in nucleus accumbens. Brain Res. (2007)
  257. Rastegar K, et al. The Effect of Intra-CA1 Agmatine Microinjection on Water Maze Learning and Memory in Rat. Iran Red Crescent Med J. (2011)
  258. Stewart LS, McKay BE. Acquisition deficit and time-dependent retrograde amnesia for contextual fear conditioning in agmatine-treated rats. Behav Pharmacol. (2000)
  259. McKay BE, et al. Learning and memory in agmatine-treated rats. Pharmacol Biochem Behav. (2002)
  260. Rushaidhi M, et al. Agmatine selectively improves behavioural function in aged male Sprague-Dawley rats. Neuroscience. (2012)
  261. Liu P, et al. Behavioral effects of intracerebroventricular microinfusion of agmatine in adult rats. Behav Neurosci. (2008)
  262. Liu P, Collie ND. Behavioral effects of agmatine in naive rats are task- and delay-dependent. Neuroscience. (2009)
  263. Szabó C. Physiological and pathophysiological roles of nitric oxide in the central nervous system. Brain Res Bull. (1996)
  264. Demehri S, et al. Agmatine exerts anticonvulsant effect in mice: modulation by alpha 2-adrenoceptors and nitric oxide. Neuropharmacology. (2003)
  265. Bence AK, et al. An in vivo evaluation of the antiseizure activity and acute neurotoxicity of agmatine. Pharmacol Biochem Behav. (2003)
  266. Luszczki JJ, et al. Agmatine enhances the anticonvulsant action of phenobarbital and valproate in the mouse maximal electroshock seizure model. J Neural Transm. (2008)
  267. Anticonvulsive effect of agmatine in mice.
  268. Nitric oxide mediates glutamate-linked enhancement of cGMP levels in the cerebellum.
  269. Garthwaite J, Charles SL, Chess-Williams R. Endothelium-derived relaxing factor release on activation of NMDA receptors suggests role as intercellular messenger in the brain. Nature. (1988)
  270. Schoemaker H. Polyamines allosterically modulate {3H}nitrendipine binding to the voltage-sensitive calcium channel in rat brain. Eur J Pharmacol. (1992)
  271. Jeong SY, et al. Nitric oxide directly activates large conductance Ca2+-activated K+ channels (rSlo). Mol Cells. (2001)
  272. Shin JH, et al. Nitric oxide directly activates calcium-activated potassium channels from rat brain reconstituted into planar lipid bilayer. FEBS Lett. (1997)
  273. Denninger JW, Marletta MA. Guanylate cyclase and the .NO/cGMP signaling pathway. Biochim Biophys Acta. (1999)
  274. Bhutada P, et al. Agmatine, an endogenous ligand of imidazoline receptor protects against memory impairment and biochemical alterations in streptozotocin-induced diabetic rats. Prog Neuropsychopharmacol Biol Psychiatry. (2012)
  275. Hwang SL, et al. Activation of imidazoline receptors in adrenal gland to lower plasma glucose in streptozotocin-induced diabetic rats. Diabetologia. (2005)
  276. Bergin DH, Liu P. Agmatine protects against beta-amyloid25-35-induced memory impairments in the rat. Neuroscience. (2010)
  277. Matheus FC, et al. Neuroprotective effects of agmatine in mice infused with a single intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Behav Brain Res. (2012)
  278. Moosavi M, et al. Agmatine protects against scopolamine-induced water maze performance impairment and hippocampal ERK and Akt inactivation. Neuropharmacology. (2012)
  279. Utkan T, et al. Agmatine, a metabolite of L-arginine, reverses scopolamine-induced learning and memory impairment in rats. Pharmacol Biochem Behav. (2012)
  280. Zarifkar A, et al. Agmatine prevents LPS-induced spatial memory impairment and hippocampal apoptosis. Eur J Pharmacol. (2010)
  281. Ahn SK, et al. Protective effects of agmatine on lipopolysaccharide-injured microglia and inducible nitric oxide synthase activity. Life Sci. (2012)
  282. Kohl S, et al. Prepulse inhibition in psychiatric disorders–apart from schizophrenia. J Psychiatr Res. (2013)
  283. Geyer MA, et al. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology (Berl). (2001)
  284. Giakoumaki SG. Cognitive and prepulse inhibition deficits in psychometrically high schizotypal subjects in the general population: relevance to schizophrenia research. J Int Neuropsychol Soc. (2012)
  285. Uzbay T, et al. Agmatine disrupts prepulse inhibition of acoustic startle reflex in rats. J Psychopharmacol. (2010)
  286. Pålsson E, et al. Agmatine attenuates the disruptive effects of phencyclidine on prepulse inhibition. Eur J Pharmacol. (2008)
  287. Kotagale NR, et al. Psychopharmacological study of agmatine in behavioral tests of schizophrenia in rodents. Pharmacol Biochem Behav. (2012)
  288. Liu P, et al. Age-related changes in nitric oxide synthase and arginase in the rat prefrontal cortex. Neurobiol Aging. (2004)
  289. Liu P, et al. Effects of aging on agmatine levels in memory-associated brain structures. Hippocampus. (2008)
  290. Liu P, et al. Age-related changes in polyamines in memory-associated brain structures in rats. Neuroscience. (2008)
  291. Gupta N, et al. Ageing alters behavioural function and brain arginine metabolism in male Sprague-Dawley rats. Neuroscience. (2012)
  292. Liu P, et al. Potential involvement of NOS and arginase in age-related behavioural impairments. Exp Gerontol. (2004)
  293. Liu P, et al. Hippocampal nitric oxide synthase and arginase and age-associated behavioral deficits. Hippocampus. (2005)
  294. Rushaidhi M, Zhang H, Liu P. Effects of prolonged agmatine treatment in aged male Sprague-Dawley rats. Neuroscience. (2013)
  295. Joshi MS, et al. Receptor-mediated activation of nitric oxide synthesis by arginine in endothelial cells. Proc Natl Acad Sci U S A. (2007)
  296. Haulică I, et al. Preliminary research on possible relationship of NO with agmatine at the vascular level. Rom J Physiol. (1999)
  297. Schwartz D, et al. Agmatine affects glomerular filtration via a nitric oxide synthase-dependent mechanism. Am J Physiol. (1997)
  298. Fill M, Copello JA. Ryanodine receptor calcium release channels. Physiol Rev. (2002)
  299. Nitric Oxide-induced Mobilization of Intracellular Calcium via the Cyclic ADP-ribose Signaling Pathway.
  300. Stoyanovsky D, et al. Nitric oxide activates skeletal and cardiac ryanodine receptors. Cell Calcium. (1997)
  301. Galione A, Lee HC, Busa WB. Ca(2+)-induced Ca2+ release in sea urchin egg homogenates: modulation by cyclic ADP-ribose. Science. (1991)
  302. Lee HC, Galione A, Walseth TF. Cyclic ADP-ribose: metabolism and calcium mobilizing function. Vitam Horm. (1994)
  303. Satriano J, et al. Effects on kidney filtration rate by agmatine requires activation of ryanodine channels for nitric oxide generation. Am J Physiol Renal Physiol. (2008)
  304. Jagnandan D, Sessa WC, Fulton D. Intracellular location regulates calcium-calmodulin-dependent activation of organelle-restricted eNOS. Am J Physiol Cell Physiol. (2005)
  305. Liou SF, et al. The vasorelaxing action of labedipinedilol-A involves endothelial cell-derived NO and eNOS expression caused by calcium influx. J Cardiovasc Pharmacol. (2005)
  306. eNOS at a glance.
  307. Kakizawa S, Yamazawa T, Iino M. Nitric oxide-induced calcium release: activation of type 1 ryanodine receptor by endogenous nitric oxide. Channels (Austin). (2013)
  308. Chen CT, et al. Activation of imidazoline I-2B receptor by metformin to increase glucose uptake in skeletal muscle. Horm Metab Res. (2011)
  309. Yamboliev IA, Mutafova-Yambolieva VN. PI3K and PKC contribute to membrane depolarization mediated by alpha2-adrenoceptors in the canine isolated mesenteric vein. BMC Physiol. (2005)
  310. Lu XL, et al. Marine cyclotripeptide X-13 promotes angiogenesis in zebrafish and human endothelial cells via PI3K/Akt/eNOS signaling pathways. Mar Drugs. (2012)
  311. Shi F, et al. Effects of simulated microgravity on human umbilical vein endothelial cell angiogenesis and role of the PI3K-Akt-eNOS signal pathway. PLoS One. (2012)
  312. Jung HJ, et al. Agmatine promotes the migration of murine brain endothelial cells via multiple signaling pathways. Life Sci. (2013)
  313. Auguet M, et al. Selective inhibition of inducible nitric oxide synthase by agmatine. Jpn J Pharmacol. (1995)
  314. Jianmongkol S, et al. Aminoguanidine-mediated inactivation and alteration of neuronal nitric-oxide synthase. J Biol Chem. (2000)
  315. Wolff DJ, Lubeskie A. Aminoguanidine is an isoform-selective, mechanism-based inactivator of nitric oxide synthase. Arch Biochem Biophys. (1995)
  316. Nakatsuka M, Nakatsuka K, Osawa Y. Metabolism-based inactivation of penile nitric oxide synthase activity by guanabenz. Drug Metab Dispos. (1998)
  317. Li Q, et al. Effect of agmatine on intracellular free calcium concentration in isolated rat ventricular myocytes. Sheng Li Xue Bao. (2002)
  318. Li Q, Yin JX, He RR. Effect of agmatine on L-type calcium current in rat ventricular myocytes. Acta Pharmacol Sin. (2002)
  319. Lortie MJ, et al. Agmatine, a bioactive metabolite of arginine. Production, degradation, and functional effects in the kidney of the rat. J Clin Invest. (1996)
  320. Gao Y, et al. Agmatine: a novel endogenous vasodilator substance. Life Sci. (1995)
  321. Ishikawa T, et al. N omega-hydroxyagmatine: a novel substance causing endothelium-dependent vasorelaxation. Biochem Biophys Res Commun. (1995)
  322. Gill F, et al. Effects of agmatine on the survival rate in rats bled to hemorrhage. Arzneimittelforschung. (2011)
  323. Ernsberger P, et al. Hypotensive action of clonidine analogues correlates with binding affinity at imidazole and not alpha-2-adrenergic receptors in the rostral ventrolateral medulla. J Hypertens Suppl. (1988)
  324. Ernsberger P, et al. Role of imidazole receptors in the vasodepressor response to clonidine analogs in the rostral ventrolateral medulla. J Pharmacol Exp Ther. (1990)
  325. Jou SB, Liu IM, Cheng JT. Activation of imidazoline receptor by agmatine to lower plasma glucose in streptozotocin-induced diabetic rats. Neurosci Lett. (2004)
  326. Schäfer U, et al. Effects of agmatine on the cardiovascular system of spontaneously hypertensive rats. Ann N Y Acad Sci. (1999)
  327. Sun MK, Regunathan S, Reis DJ. Cardiovascular responses to agmatine, a clonidine-displacing substance, in anesthetized rat. Clin Exp Hypertens. (1995)
  328. Khan S, et al. Beta-endorphin decreases fatigue and increases glucose uptake independently in normal and dystrophic mice. Muscle Nerve. (2005)
  329. Cheng JT, et al. Plasma glucose-lowering effect of beta-endorphin in streptozotocin-induced diabetic rats. Horm Metab Res. (2002)
  330. Evans AA, Khan S, Smith ME. Evidence for a hormonal action of beta-endorphin to increase glucose uptake in resting and contracting skeletal muscle. J Endocrinol. (1997)
  331. Radosevich PM, et al. Beta-endorphin inhibits glucose production in the conscious dog. J Clin Invest. (1984)
  332. Curry DL, Bennett LL, Li CH. Stimulation of insulin secretion by beta-endorphins (1-27 & 1-31). Life Sci. (1987)
  333. Hauner H, et al. Endogenous opiates do not influence glucose and lipid metabolism in rat adipocytes. Exp Clin Endocrinol. (1988)
  334. Kalra SP, et al. Agmatine, a novel hypothalamic amine, stimulates pituitary luteinizing hormone release in vivo and hypothalamic luteinizing hormone-releasing hormone release in vitro. Neurosci Lett. (1995)
  335. Hong S, et al. Agmatine protects retinal ganglion cells from hypoxia-induced apoptosis in transformed rat retinal ganglion cell line. BMC Neurosci. (2007)
  336. Hong S, et al. Ocular hypotensive effects of topically administered agmatine in a chronic ocular hypertensive rat model. Exp Eye Res. (2010)
  337. Hong S, et al. Retinal protective effects of topically administered agmatine on ischemic ocular injury caused by transient occlusion of the ophthalmic artery. Braz J Med Biol Res. (2012)
  338. Al Masri AA, El Eter E. Agmatine induces gastric protection against ischemic injury by reducing vascular permeability in rats. World J Gastroenterol. (2012)
  339. Utkan T, et al. Investigation on the mechanism involved in the effects of agmatine on ethanol-induced gastric mucosal injury in rats. Life Sci. (2000)
  340. Glavin GB, Smyth DD. Effects of the selective I1 imidazoline receptor agonist, moxonidine, on gastric secretion and gastric mucosal injury in rats. Br J Pharmacol. (1995)
  341. Glavin GB, Carlisle MA, Smyth DD. Agmatine, an endogenous imidazoline receptor agonist, increases gastric secretion and worsens experimental gastric mucosal injury in rats. J Pharmacol Exp Ther. (1995)
  342. Zádori ZS, et al. Imidazoline versus alpha2-adrenoceptors in the control of gastric motility in mice. Eur J Pharmacol. (2013)
  343. Molderings GJ, et al. Potential relevance of agmatine as a virulence factor of Helicobacter pylori. Dig Dis Sci. (1999)
  344. Bidet M, et al. Video microscopy of intracellular pH in primary cultures of rabbit proximal and early distal tubules. Pflugers Arch. (1990)
  345. Jurkiewicz NH, et al. Functional properties of agmatine in rat vas deferens. Eur J Pharmacol. (1996)
  346. Santos WC, et al. Dual effect of agmatine in the bisected rat vas deferens. J Pharm Pharmacol. (2003)
  347. Presta A, et al. Substrate binding and calmodulin binding to endothelial nitric oxide synthase coregulate its enzymatic activity. Nitric Oxide. (1997)
  348. Aglawe MM, et al. Participation of central imidazoline binding sites in antinociceptive effect of ethanol and nicotine in rats. Fundam Clin Pharmacol. (2013)
  349. Ozden O, et al. Agmatine blocks ethanol-induced locomotor hyperactivity in male mice. Eur J Pharmacol. (2011)
  350. Sameer SM, Chakraborty SS, Ugale RR. Agmatine attenuates acquisition but not the expression of ethanol conditioned place preference in mice: a role for imidazoline receptors. Behav Pharmacol. (2013)
  351. Uzbay T, et al. Sex-related effects of agmatine on caffeine-induced locomotor activity in Swiss Webster mice. Eur J Pharmacol. (2010)
  352. MATERIAL SAFETY DATA SHEET Agmatine.